Optherion obtains rights for newest AMD treatment

November 1, 2007

New Haven, CT-Optherion Inc., among the newest companies to attempt treatments for age-related macular degeneration (AMD), just licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on chromosome 10.

New Haven, CT-Optherion Inc., among the newest companies to attempt treatments for age-related macular degeneration (AMD), just licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on chromosome 10.

In 2005, scientists from the University of Pittsburgh published findings of a link between chromosomes 10, specifically LOC387715 and HTRA1 genes, and AMD.

If genetic tests can identify people at risk of developing AMD, then physicians can take action more aggressively and at an earlier stage with lifestyle changes and therapies, according to Optherion.

"We are optimistic that the innovative discoveries we are licensing will lead to diagnostic tests that can help change the current paradigm of AMD risk assessment and patient care," said Colin J. Foster, president and chief executive officer of Optherion.